Vamil Divan
Stock Analyst at Guggenheim
(4.86)
# 73
Out of 5,147 analysts
248
Total ratings
70.39%
Success rate
21.66%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $122 → $140 | $123.82 | +13.07% | 15 | Feb 6, 2026 | |
| AMGN Amgen | Maintains: Neutral | $305 → $347 | $388.16 | -10.60% | 2 | Feb 6, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $227 → $240 | $248.43 | -3.39% | 19 | Jan 23, 2026 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $115 → $124 | $73.90 | +67.79% | 14 | Jan 16, 2026 | |
| INSM Insmed | Maintains: Buy | $230 → $221 | $149.33 | +47.99% | 8 | Dec 18, 2025 | |
| PFE Pfizer | Maintains: Buy | $33 → $35 | $27.65 | +26.58% | 23 | Nov 24, 2025 | |
| JBIO Jade Biosciences | Maintains: Buy | $14 → $17 | $14.83 | +14.63% | 2 | Nov 18, 2025 | |
| ELDN Eledon Pharmaceuticals | Maintains: Buy | $9 → $8 | $2.62 | +205.34% | 1 | Nov 18, 2025 | |
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.75 | +300.00% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $232.08 | +4.27% | 28 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $11 | $6.02 | +82.72% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $13 | $11.09 | +17.22% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $39 | $29.84 | +30.70% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.24 | +212.50% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $6.93 | +765.80% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $29.79 | +57.77% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.74 | +264.96% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $40.79 | +49.55% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $14.19 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $4.56 | +470.18% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.42 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $24.56 | -22.64% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $132.25 | -25.90% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $30.10 | +12.96% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.32 | +201.20% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $163.89 | -70.10% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $1,051.99 | -66.16% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $6.12 | -1.96% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $11.52 | +1,236.81% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $4.30 | +248.84% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $33.66 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $33.86 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $18.26 | -17.85% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $62.37 | -2.20% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $3.35 | +2,974.63% | 3 | Jan 17, 2018 |
Merck & Co.
Feb 6, 2026
Maintains: Buy
Price Target: $122 → $140
Current: $123.82
Upside: +13.07%
Amgen
Feb 6, 2026
Maintains: Neutral
Price Target: $305 → $347
Current: $388.16
Upside: -10.60%
Johnson & Johnson
Jan 23, 2026
Maintains: Buy
Price Target: $227 → $240
Current: $248.43
Upside: -3.39%
ANI Pharmaceuticals
Jan 16, 2026
Maintains: Buy
Price Target: $115 → $124
Current: $73.90
Upside: +67.79%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $230 → $221
Current: $149.33
Upside: +47.99%
Pfizer
Nov 24, 2025
Maintains: Buy
Price Target: $33 → $35
Current: $27.65
Upside: +26.58%
Jade Biosciences
Nov 18, 2025
Maintains: Buy
Price Target: $14 → $17
Current: $14.83
Upside: +14.63%
Eledon Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.62
Upside: +205.34%
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.75
Upside: +300.00%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $232.08
Upside: +4.27%
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $6.02
Upside: +82.72%
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $11.09
Upside: +17.22%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $29.84
Upside: +30.70%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.24
Upside: +212.50%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $6.93
Upside: +765.80%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $29.79
Upside: +57.77%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.74
Upside: +264.96%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $40.79
Upside: +49.55%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $14.19
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $4.56
Upside: +470.18%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.42
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $24.56
Upside: -22.64%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $132.25
Upside: -25.90%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $30.10
Upside: +12.96%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $3.32
Upside: +201.20%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $163.89
Upside: -70.10%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $1,051.99
Upside: -66.16%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $6.12
Upside: -1.96%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $11.52
Upside: +1,236.81%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $4.30
Upside: +248.84%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $33.66
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $33.86
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $18.26
Upside: -17.85%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $62.37
Upside: -2.20%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $3.35
Upside: +2,974.63%